Chronic Obstructive Pulmonary Disease (COPD) presents a significant health and economic challenge in the UK, standing as the second most common lung condition after asthma. With over 1.2 million individuals diagnosed, the disease imposes a considerable £800 million annual cost on the NHS, with advanced stages of COPD requiring nearly tenfold the resources compared to its milder stages. This situation highlights a critical need to shift our focus towards proactive prevention, not merely treatment.

Our Client's Innovative Approach:

NEPeSMO Limited has emerged at the forefront of this challenge, marrying advanced AI analytics with smart digital monitoring. Their flagship innovation, COPDPredict™, exemplifies their forward-thinking ethos by offering continuous and comprehensive monitoring of COPD patients. The platform meticulously tracks patient data, including daily wellness assessments, spirometry readings, and blood test results, to anticipate potential COPD exacerbations. This predictive prowess empowers clinicians to intervene pre-emptively, aiming to curtail exacerbation frequency and diminish the associated hospitalisation risks.

The initiative's precision was honed through robust clinical trials involving 384 patients across NHS hospitals, enhancing the data-driven accuracy of COPDPredict™.  

‍

Our Reflective Pride:

NEPeSMO stands as a testament to the transformative power of R&D coupled with seeking support with financing mechanisms and opportunities open to them. At Inventya, we take immense pride in partnering with companies like NEPeSMO and are humbled by their kind words of acknowledgement. 

Embark on Your Funding Journey with Inventya

Inspired by NEPesMO’s journey? Contact Inventya for a free consultation tailored to your business’s needs.  

Schedule Your Consultation with Inventya

‍